Country

MERZ NEUROSCIENCES ANNOUNCES NEW SURVEY FINDINGS THAT SHOWCASE LACK OF AWARENESS OF UPPER LIMB SPASTICITY (ULS). More than 8 in 10 Americans Say They Have Never Heard of ULS

Merz Neurosciences, a division of Merz North America (US affiliate of the global Merz Pharma Group), today announced findings from a new survey of more than 1,000 US adults, revealing that overall awareness of the signs and symptoms of adult Upper Limb Spasticity (ULS) is low among Americans. The survey was conducted by Harris Poll and commissioned by Merz Neurosciences. In adults with upper limb spasticity, there is an imbalance of signals from the brain to the muscles, which causes stiffness and spasms. This can lead to abnormal arm or hand positions, uncomfortable movement, and pain1.

“Adult ULS is a serious condition that impacts many Americans after stroke, injury, and other neurological disorders, preventing them from being able to do simple, day-to-day activities, like getting dressed or putting on deodorant,” said Robyn Moore, CEO of the National Stroke Association. “Since ULS can happen months after the initial stroke or injury, it’s critical that family members and caregivers be able to recognize the symptoms.”

The national survey was conducted online among 1,043 U.S. adults from November 9-20, 2015 and asked adults about their familiarity with ULS. The survey found:

• More than 8 in 10 Americans (83%) say they have never heard of ULS.

• More than 2 in 3 Americans (67%) admit not being sure of the early signs and symptoms of ULS.

• About 1 in 3 (32%) identified at least one condition that could lead to ULS; still, the majority (59%) report being unclear on the causes of ULS.

• About 1 in 4 believe that upper limb spasticity is extremely rare in people who have had a stroke.

• Further, about 1 in 4 (24% of Americans and 28% of the undiagnosed who are aware of ULS) believe adults who have suffered from a stroke should not be concerned about upper limb spasticity.

An estimated 1 million Americans are currently suffering from upper limb spasticity and dealing with the issues that come with the condition, as well as the pain and discomfort,” stated Glenn Block, Vice President and Head of Merz Neurosciences. “That’s why Merz Neurosciences has committed to identifying and researching treatments for people with movement disorders, like ULS.”

Merz Neurosciences recently announced FDA approval of Xeomin® (incobotulinumtoxinA) for the treatment of upper limb spasticity in adults. In clinical studies, treatment with Xeomin for adult ULS resulted in statistically significant improvements in muscle tone, with a safety profile similar to that observed for other Xeomin indications.

For more information, please see XEOMIN full Prescribing Information and Medication Guide.

Survey Methodology

This survey was conducted online within the United States by Harris Poll on behalf of Merz Neurosciences between November 9-20, 2015 among 1,043 U.S. adults 18+. Figures for age, sex, race/ethnicity, education, region and household income were weighted, where necessary, to bring them into line with their actual proportions in the population. Propensity score weighting was used to adjust for respondents’ propensity to be online.

All sample surveys and polls, whether or not they use probability (random) sampling, are subject to multiple sources of error which are most often not possible to quantify or estimate, including sampling error, coverage error, error associated with nonresponse, error associated with question wording and response options, and post-survey weighting and adjustments. Therefore, the words “margin of error” are avoided as they are misleading. All that can be calculated are different possible sampling errors with different probabilities for pure, unweighted, random samples with 100% response rates. These are only theoretical because no published polls come close to this ideal.

Respondents for this survey were selected from among those who have agreed to participate in Harris Poll surveys. Because the sample is based on those who agreed to participate in the panel, no estimates of theoretical sampling error can be calculated.

About XEOMIN® (incobotulinumtoxinA)

Xeomin® (incobotulinumtoxinA) is a prescription medicine that is injected into muscles and used to treat increased muscle stiffness in the arm of adults with upper limb spasticity, the abnormal head position and neck pain that happens with cervical dystonia (CD) in adults, and to treat abnormal spasm of the eyelids (blepharospasm) in adults who have had prior treatment with onabotulinumtoxinA (Botox®).

About Merz Neurosciences

Merz Neurosciences is a division of Merz North America, a specialty healthcare company that is dedicated to delivering a better total experience in aesthetics, dermatology, and neurosciences. By working side by side with physicians and patients, Merz Neurosciences strives to deliver meaningful treatment options and

a better patient experience in order to meet the needs of each person we serve. Merz Neurosciences is an important contributor to the U.S. neurosciences space, offering a well-balanced product portfolio that includes the neurotoxin Xeomin® (incobotulinumtoxinA), the anticholinergic Cuvposa® (glycopyrrolate) Oral Solution and the Prolaryn® injectable implant family of products.

To learn more about Merz Neurosciences and their U.S. product portfolio, please visit www.merzusa.com/neurosciences. XEOMIN® IMPORTANT CONSUMER SAFETY INFORMATION

Read the Medication Guide before you start receiving XEOMIN® (Zeo-min) and each time XEOMIN® is given to you as there may be new information. The risk information provided here is not comprehensive. To learn more:

• Talk to your health care provider or pharmacist

• Visit www.xeomin.com to obtain the FDA-approved product labeling

• Call 1-888-4-XEOMIN

Uses XEOMIN® is a prescription medicine that is injected into muscles and used to treat:

• increased muscle stiffness in the arm of adults with upper limb spasticity

• abnormal head position and neck pain in adults with cervical dystonia (CD)

• abnormal spasm of the eyelids (blepharospasm) in adults who have had prior treatment with onabotulinumtoxinA (BOTOX®)

It is not known whether XEOMIN® is safe or effective in children.

Warnings

XEOMIN® may cause serious side effects that can be life threatening. Call your doctor or get medical help right away if you have any of these problems anytime (hours to week) after treatment with XEOMIN®:

Problems with swallowing, speaking, or breathing can happen within hours to weeks after an injection of XEOMIN® if the muscles that you use to breathe and swallow become weak. Death can happen as a complication if you have severe problems with swallowing or breathing after treatment with XEOMIN®.

• People with certain breathing problems may need to use muscles in their neck to help them breathe and may be at greater risk for serious breathing problems with XEOMIN®.

• Swallowing problems may last for several months, and during that time you may need a feeding tube to receive food and water. If swallowing problems are severe, food or liquids may go into your lungs. People who already have swallowing or breathing problems before receiving XEOMIN® have the highest risk of getting these problems.

Spread of toxin effects. In some cases, the effect of botulinum toxin may

Download File:
04.11.2016 [ 0 KB ]

Press Contact

Merz North America

Emily Browder
Corporate Communications

 

Phone: +1 919.582.8114

Merz in the Americas

Merz has a direct presence in six countries in the Americas, as well as a network of selected professional distribution partners in South and Central America and the Caribbean. Merz in the Americas is headquartered in Raleigh, North Carolina, and has facilities in Mesa, Arizona, Franksville, Wisconsin as well as offices in Toronto, Canada, Mexico City, Bogotá, Colombia, São Paolo, Brazil and Buenos Aires, Argentina.

Merz Worldwide

With approximately 3,000 employees and a direct presence in 28 countries, Merz is a global, family-owned aesthetics and neurotoxin company based in Frankfurt, Germany. Privately held for 110 years, the company is distinguished by its commitment to innovation, long-term perspective and focus on profitable growth. In addition to its comprehensive portfolio of medical aesthetic products in the device, injectable and skincare categories, Merz also develops neurotoxin therapy to treat neurologically-induced movement disorders. In fiscal year 2016/17, Merz generated revenue of EUR 1,092.9 million. More information is available at www.merz.com.

Media Contact – Global

Merz Pharma GmbH & Co. KGaA
Global Corporate Communications
Mariana Smith Bourland
Phone: +49 151 4249 1466
Email: mariana.smith@merz.com

Media Contact – North America

Merz North America, Inc.
Corporate Communications
Emily Browder
Phone: +1 919.582.8114
Email: Emily.Browder@merz.com